{"id":"https://genegraph.clinicalgenome.org/r/c1f66f39-fca7-4b6e-b0f4-4a0651420062v1.0","type":"EvidenceStrengthAssertion","dc:description":"The gene *AKR1D1* has been definitively associated with the disease Congenital Bile Acid Synthesis Defect 2 according to the gene–disease association criteria of the ACMG (SOP version 11). This disease results from an anomaly of bile acid synthesis and is characterized by severe and rapidly progressive cholestatic liver disease, and malabsorption of fat and fat-soluble vitamins. Homozygous or compound heterozygous mutations in the AKR1D1 gene cause this disease.\n\nMutations in *AKR1D1* cause congenital bile acid synthesis defect type 2 by impairing the enzyme 3-oxo-5-β-steroid 4-dehydrogenase. This enzyme, crucial for bile acid production, is responsible for the NADPH-dependent conversion of 5beta-cholestan-3-one to cholest-4-en-3-one. Impaired conversion leads to abnormal bile acids, cholesterol buildup, and fat-soluble vitamin deficiencies (PMID: 30809085). The AKR1D1 enzyme's biochemical disruptions were initially identified using FAB-MS, revealing high 3-oxo-Δ4 bile acids and low normal bile acid conjugates in urine (PMID: 1735522). Affected infants present with symptoms of jaundice, failure to thrive, and steatorrhea. Timely diagnosis is vital because the liver disease associated with this condition can be life-threatening (it can lead to cirrhosis and death), yet it can be managed with oral primary bile acid replacement (PMID: 30809085).\n\n**Summary of Case Level Data (10.2 points)**: 10 probands were scored with 7 variants (2 frameshift, 1 nonsense, 5 missense) from 4 publications (PMID: 23679950, 35758383, 12970144, 23323017).\n\n**Summary of Experimental Evidence (2.5 points)**: AKR1D1 knockout mice indicated sex-specific metabolic alterations. Male knockout mice had enhanced insulin sensitivity and decreased lipid buildup in the liver and adipose tissue, but had higher triglyceride levels and intramuscular triacylglycerol. These findings underline AKR1D1's important function in regulating bile acid synthesis and metabolic balance in a sex-specific way.  (PMID: 35318963). Another study characterized AKR1D1 mutations. Clinically relevant mutants showed reduced activity, decreased stability, and heightened thermolability. One mutant (P133R) exhibited uncompetitive kinetics and lower catalytic efficiency, compromising bile acid synthesis and leading to potential bile acid deficiency syndromes ​(PMID: 20522910).\n\nIn summary, experimental and clinical evidence consistently supports a definitive gene-disease association between AKR1D1 and autosomal recessive congenital bile acid synthesis defect due to AKR1D1. This classification was approved by the ClinGen IEM GCEP on September 22, 2024 (SOP Version 11).\n\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/c1f66f39-fca7-4b6e-b0f4-4a0651420062","GCISnapshot":"https://genegraph.clinicalgenome.org/r/236a7baf-2425-4882-a6de-130dfb5117ac","calculatedEvidenceStrength":"Strong","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/236a7baf-2425-4882-a6de-130dfb5117ac_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10097","date":"2024-09-27T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/236a7baf-2425-4882-a6de-130dfb5117ac_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10097","date":"2024-10-10T18:14:14.602Z","role":"Publisher"}],"curationReasonDescription":"The role of AKR1D1 in Congenital Bile Acid Synthesis Defect 2 has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.","curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/236a7baf-2425-4882-a6de-130dfb5117ac_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e351f8e0-2174-4487-a80c-01946dea5482_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7f17315-c09b-4ad9-9151-5c60f496e7b6","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7f17315-c09b-4ad9-9151-5c60f496e7b6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Detection of 5β-reductase activity of AKR1D1 and its natural mutants in transfected HEK 293 cells. ","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/d7f17315-c09b-4ad9-9151-5c60f496e7b6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12970144","allele":{"id":"https://genegraph.clinicalgenome.org/r/4940046b-73a4-4e81-824c-697492b33499","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"AKR1D1, 1-BP DEL, 511T","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/5375"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/e351f8e0-2174-4487-a80c-01946dea5482","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12970144","rdfs:label":"H A Lemonde et.al (2003) : Patient BH","allele":{"id":"https://genegraph.clinicalgenome.org/r/4940046b-73a4-4e81-824c-697492b33499"},"firstTestingMethod":"Exome sequencing","previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/d7f17315-c09b-4ad9-9151-5c60f496e7b6_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/8c1b7063-ee6b-4ac5-a324-27ae41c7f1ab_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7e0ea8ca-af6c-4243-a417-43c1d55f297b","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7e0ea8ca-af6c-4243-a417-43c1d55f297b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35758383","allele":{"id":"https://genegraph.clinicalgenome.org/r/6bd0ebf3-fe1e-4299-9f30-08b7c21e21af","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005989.4(AKR1D1):c.797G>A (p.Arg266Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA4502829"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/8c1b7063-ee6b-4ac5-a324-27ae41c7f1ab","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35758383","rdfs:label":"Anh-Hoa Nguyen Pham et.al (2022) : Patient 1","allele":{"id":"https://genegraph.clinicalgenome.org/r/6bd0ebf3-fe1e-4299-9f30-08b7c21e21af"},"firstTestingMethod":"Exome sequencing","previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/7e0ea8ca-af6c-4243-a417-43c1d55f297b_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/9fe00974-9377-46e8-a93f-20c656010ec3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c6f4bff5-73e4-4e30-ace9-98909ed34799","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c6f4bff5-73e4-4e30-ace9-98909ed34799_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35758383","allele":{"id":"https://genegraph.clinicalgenome.org/r/6bd0ebf3-fe1e-4299-9f30-08b7c21e21af"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/9fe00974-9377-46e8-a93f-20c656010ec3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35758383","rdfs:label":"Anh-Hoa Nguyen Pham et.al (2022) : Patient 2","allele":{"id":"https://genegraph.clinicalgenome.org/r/6bd0ebf3-fe1e-4299-9f30-08b7c21e21af"},"firstTestingMethod":"Exome sequencing","previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/c6f4bff5-73e4-4e30-ace9-98909ed34799_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/04ef73cc-d098-46ca-aecb-55725ae7fdce_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/17fa45ab-cd0d-4751-8c57-8c204fd5dcd1","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/17fa45ab-cd0d-4751-8c57-8c204fd5dcd1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23679950","allele":{"id":"https://genegraph.clinicalgenome.org/r/a438673f-85d0-4a5d-a351-b03475a2dbd0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005989.4(AKR1D1):c.587del (p.Cys196SerfsTer11)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA578193339"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/04ef73cc-d098-46ca-aecb-55725ae7fdce","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23679950","rdfs:label":"Morgan et. al (2013) - V:4 (P1)","allele":{"id":"https://genegraph.clinicalgenome.org/r/a438673f-85d0-4a5d-a351-b03475a2dbd0"},"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/17fa45ab-cd0d-4751-8c57-8c204fd5dcd1_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/bef5f1a5-1a9c-43c8-8812-3bcfe96d9e02_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6b4fd93e-43c2-4f1a-bae8-bde857431a7e","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6b4fd93e-43c2-4f1a-bae8-bde857431a7e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23323017","allele":{"id":"https://genegraph.clinicalgenome.org/r/19ef4180-d26c-4fc6-bf4f-ca6088390156","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005989.4(AKR1D1):c.396C>A (p.Tyr132del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA369360433"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/7800a045-5718-4819-9317-fab7fb87da9c","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7800a045-5718-4819-9317-fab7fb87da9c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23323017","allele":{"id":"https://genegraph.clinicalgenome.org/r/6bd0ebf3-fe1e-4299-9f30-08b7c21e21af"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/bef5f1a5-1a9c-43c8-8812-3bcfe96d9e02","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23323017","rdfs:label":"Jing Zhao et.al(2012) : Patient 2","allele":[{"id":"https://genegraph.clinicalgenome.org/r/6bd0ebf3-fe1e-4299-9f30-08b7c21e21af"},{"id":"https://genegraph.clinicalgenome.org/r/19ef4180-d26c-4fc6-bf4f-ca6088390156"}],"firstTestingMethod":"Exome sequencing","previousTesting":false,"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/7800a045-5718-4819-9317-fab7fb87da9c_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/6b4fd93e-43c2-4f1a-bae8-bde857431a7e_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/ff89b7f3-32b9-4c21-b9cb-448f3f87f645_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/226fb48f-e797-455e-9845-7b14eaaf0ea4","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/226fb48f-e797-455e-9845-7b14eaaf0ea4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35758383","allele":{"id":"https://genegraph.clinicalgenome.org/r/9f802ba1-36f8-4228-8b79-89542188e209","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005989.4(AKR1D1):c.155T>C (p.Ile52Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA4502589"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/ff89b7f3-32b9-4c21-b9cb-448f3f87f645","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35758383","rdfs:label":"Anh-Hoa Nguyen Pham et.al (2022) : Patient 3","allele":{"id":"https://genegraph.clinicalgenome.org/r/9f802ba1-36f8-4228-8b79-89542188e209"},"firstTestingMethod":"Exome sequencing","previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/226fb48f-e797-455e-9845-7b14eaaf0ea4_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/f02f305d-37fc-4083-bd91-77798fa5cde3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/83bb943a-be04-43f2-abf5-4ffe447d96ab","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/83bb943a-be04-43f2-abf5-4ffe447d96ab_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In PMID: 20522910 the authors set out to do functional studies on this P198L aka (P221L) and other variants. However, they could not purify the P198L variant due to it being found in inclusion bodies. Next they conducted transient transfection studies for the AKR1D1-P198L variant. They found extremely low levels of expression were observed for this mutant that was close to the detection limit of the polyclonal antibody. Next, to investigate whether the low expression levels of this mutant were caused by increased degradation rates, they monitored wild type and the mutant AKR1D1 protein levels over time following cycloheximide treatment. They found AKR1D1-P198L showed a mild reduction in expression level.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/83bb943a-be04-43f2-abf5-4ffe447d96ab_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12970144","allele":{"id":"https://genegraph.clinicalgenome.org/r/369cb88a-4ae8-46b7-95e4-8f55edf9916e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005989.4(AKR1D1):c.662C>T (p.Pro221Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA369362230"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/f02f305d-37fc-4083-bd91-77798fa5cde3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12970144","rdfs:label":"H A Lemonde et.al (2003) : Patient MS ","allele":{"id":"https://genegraph.clinicalgenome.org/r/369cb88a-4ae8-46b7-95e4-8f55edf9916e"},"firstTestingMethod":"Exome sequencing","previousTesting":false,"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/83bb943a-be04-43f2-abf5-4ffe447d96ab_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/6343621f-07ff-48ef-b807-5281a8d0e6b0_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f67c757c-ea14-49c8-9991-6e2e421d4517","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f67c757c-ea14-49c8-9991-6e2e421d4517_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In PMID: 20522910 the authors set out to do functional studies on this L106F and other variants. However, they could not purify the L106F variant due to it being found in inclusion bodies. Next they conducted transient transfection studies for the AKR1D1-L106F variant. They found extremely low levels of expression were observed for this mutant that was close to the detection limit of the polyclonal antibody. Next, to investigate whether the low expression levels of this mutant were caused by increased degradation rates, they monitored wild type and the mutant AKR1D1 protein levels over time following cycloheximide treatment. They found AKR1D1-L106F was expressed very poorly and degraded within 6 h after cycloheximide treatment.\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/f67c757c-ea14-49c8-9991-6e2e421d4517_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12970144","allele":{"id":"https://genegraph.clinicalgenome.org/r/5aa5330c-015f-48c2-ba46-2966e56b3e15","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005989.4(AKR1D1):c.316C>T (p.Leu106Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA117467"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/6343621f-07ff-48ef-b807-5281a8d0e6b0","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12970144","rdfs:label":"H A Lemonde et.al (2003) : Patient RM","allele":{"id":"https://genegraph.clinicalgenome.org/r/5aa5330c-015f-48c2-ba46-2966e56b3e15"},"firstTestingMethod":"Exome sequencing","previousTesting":false,"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/f67c757c-ea14-49c8-9991-6e2e421d4517_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":10.2},{"id":"https://genegraph.clinicalgenome.org/r/236a7baf-2425-4882-a6de-130dfb5117ac_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/236a7baf-2425-4882-a6de-130dfb5117ac_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3f431351-96ea-4758-9f05-8d3decdc809a","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/37c44400-ab1b-4c82-b287-e0fe120cf584","type":"Finding","dc:description":"The study of the AKR1D1 gene in mice is similar to human phenotypes because it highlights the role of this gene in regulating bile acid synthesis and glucocorticoid clearance, both of which are crucial for metabolism. In humans, defects in bile acid synthesis can lead to metabolic disorders, similar to the findings in Akr1d1-/- mice. The sex-specific metabolic responses observed in the mice, such as differences in insulin tolerance and fat accumulation, may also reflect similar variations seen in human populations. Understanding these mechanisms in mice can provide insights into how alterations in the AKR1D1 gene might affect human health, particularly regarding metabolic diseases and conditions related to bile acid metabolism.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35318963","rdfs:label":"AKR1D1 KNOCKOUT MICE MODEL ","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/236a7baf-2425-4882-a6de-130dfb5117ac_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/074c9327-0611-42d7-9d61-ff5dbb9dfae9","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2cbe5e0d-e908-49d2-bb12-0c5450605f7c","type":"Finding","dc:description":"The phenotype observed in AKR1D1 deficiency, including disrupted bile acid and steroid hormone metabolism, liver dysfunction, and associated clinical symptoms, aligns closely with the clinical presentation of metabolic liver diseases. The consistency lies in the role of AKR1D1 in key metabolic pathways that, when disrupted, lead to the accumulation of toxic metabolites and hormonal imbalances, driving the disease phenotype observed in affected individuals.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20522910","rdfs:label":"AKR1D1 : Biochemical Function ","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2.5}],"evidenceStrength":"Definitive","sequence":9197,"specifiedBy":"GeneValidityCriteria10","strengthScore":12.7,"subject":{"id":"https://genegraph.clinicalgenome.org/r/NsU9MACJu-8","type":"GeneValidityProposition","disease":"obo:MONDO_0009339","gene":"hgnc:388","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_236a7baf-2425-4882-a6de-130dfb5117ac-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}